Business UpdateMay 19, 2026, 08:31 AM
RenovoRx Nears TIGeR-PaC Trial Enrollment Completion; Q1 Revenue Record
AI Summary
RenovoRx announced that its CEO and CFO will participate in the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026. They will discuss record first-quarter 2026 revenue of $563,000 from RenovoCath sales, accelerating adoption, and growing repeat orders. The company also expects to close enrollment for its Phase III TIGeR-PaC clinical trial in early June, completing the milestone by the end of June 2026, with final data anticipated in mid to late 2027. Additionally, they will highlight support for investigator-initiated trials and post-marketing registry studies.
Key Highlights
- CEO and CFO to present at Alliance Global Partners Annual Healthcare Company Showcase on May 20.
- Reported record first-quarter 2026 revenue of $563,000 from RenovoCath sales.
- Noted accelerating RenovoCath adoption at high-volume cancer centers and growing repeat orders.
- Expects to send notification of TIGeR-PaC trial enrollment closure in early June 2026.
- Anticipates final TIGeR-PaC clinical trial data in mid to late 2027.
- Supporting investigator-initiated trials and post-marketing registry studies.
- Generated approximately $1.1 million in RenovoCath sales for the full year 2025.
Price Impact
More from RNXT